文献速递心力衰竭与心肌病

英国心衰初级保健中醛固酮受体拮抗剂的使用:全国队列研究

Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.
PubMed 文献 · Heart · 2025-09-25

本研究基于英国初级保健电子健康记录,识别2014-2020年符合NICE指南MRA治疗标准的HFrEF患者,分析MRA处方率及影响因素。结果显示MRA处方率从41%升至55%,但仍有半数患者未接受治疗;高龄、较高eGFR、高血压及降压药处方与MRA处方呈负相关,男性、扩张型心肌病、较晚年份及沙库巴曲缬沙坦处方与MRA处方呈正相关。

要点

  • 英国HFrEF患者中MRA处方率从2014年41%升至2020年55%,仍有一半未治疗。
  • 高龄、较高eGFR、高血压及降压药使用与MRA处方不足相关。
  • 男性、扩张型心肌病、较晚年份及沙库巴曲缬沙坦处方与MRA处方增加相关。

核心结论

  • 英国HFrEF患者中MRA使用不足,尽管2014-2020年处方率增加,但半数符合条件者仍未接受治疗。
  • 高龄、性别、合并症和合并用药与MRA处方不足相关,应据此制定质量改进策略。

研究设计与样本

  • 基于英国The Health Improvement Network初级保健电子健康记录的国家队列研究。
  • 使用临床代码列表识别HFrEF患者,每年根据NICE指南标准确定MRA治疗合格者。
  • 采用混合效应逻辑回归模型分析MRA处方的影响因素。

主要发现

  • MRA处方率从41%上升至55%。
  • MRA处方与年龄(每1 SD的OR 0.02,95%CI 0.01-0.03)、较高肾小球滤过率(0.37,0.25-0.55)、高血压(0.21,0.40-0.78)及降压药处方(0.03,0.02-0.07)呈负相关。
  • MRA处方与男性(6.31,3.20-12.4)、扩张型心肌病(25.9,7.48-89.4)、研究开始后每一年(2.17,1.85-2.54)及沙库巴曲缬沙坦处方(214,56-823)呈正相关。

关键数值与推荐

  • 基于英国NICE HFrEF指南标准确定MRA治疗合格人群。

临床怎么用

  • 临床应关注高龄、较高eGFR、高血压及合并多种降压药的患者,评估MRA处方不足的原因并改进。
  • 对男性、扩张型心肌病及已使用沙库巴曲缬沙坦的患者,可考虑优先评估MRA治疗。

局限性

  • 研究基于初级保健电子健康记录,可能存在编码不准确或数据缺失。
  • 未报告MRA禁忌证、不耐受或患者偏好等可能影响处方的详细原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with reduced ejection fraction (HFrEF) but are underused, despite recommendation in key guidelines. Identifying the factors contributing to underuse and addressing adherence are key components of a learning health system. We aimed to evaluate MRA prescription in people with HFrEF who would benefit, based on the UK National Institute for Health and Care Excellence (NICE) HFrEF guideline. METHODS: We used clinical code lists to identify people with HFrEF in primary care electronic health record (EHR) data from The Health Improvement Network database. For each calendar year 2014-2020, we identified individuals who met the NICE guideline criteria for MRA therapy. We fitted mixed effects logistic regression models to determine the factors contributing to MRA prescription. RESULTS: Among 24 135 people with HFrEF studied between 2014 and 2020, 12 150 person-years were eligible for MRA treatment. The MRA prescription rate increased from 41% to 55%. MRA prescription was inversely associated with age (OR per 1 SD, 95% CI) (0.02 (0.01, 0.03)), increasing glomerular filtration rate (0.37 (0.25, 0.55)), hypertension (0.21 (0.40, 0.78)) and prescription of antihypertensives (0.03 (0.02, 0.07)). MRA prescription was associated with male gender (6.31 (3.20, 12.4)), dilated cardiomyopathy (25.9 (7.48, 89.4)), calendar year (2.17 (1.85, 2.54) per year after study start) and prescription of sacubitril/valsartan (214 (56, 823)). CONCLUSIONS: MRAs are underused in people with HFrEF in the UK. Although prescribing increased between 2014 and 2020, half of the cohort still did not receive the therapy. Older age, gender, comorbidities and co-prescriptions were linked to MRA underuse. Understanding the factors contributing to underprescribing at a population level should be used to inform quality improvement strategies.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Maclean, Chen, Lumbers, et al. Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study. Heart. 2025. PMID: 40250982. doi:10.1136/heartjnl-2024-325132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。